ライフサイエンスコーパス: partial response

1 ts achieved an overall response (complete or partial response).

2 the combined rates of complete response and partial response).

3 response, 7% very good partial response, 58% partial response).

4 ete response, and eight [12%] patients had a partial response).

5 to 32.7%; five complete responses and three partial responses).

6 ve response (three complete responses and 35 partial responses).

7 nts (5%) achieved an objective response (all partial responses).

8 t cancer achieved an objective response (all partial responses).

9 atients had a complete response, and 3 had a partial response.

10 complete response and 14 (18%; 10-28) had a partial response.

11 A relapse was defined as loss of partial response.

12 eported confirmed or unconfirmed complete or partial response.

13 one patient (6%; 95% CI 0.0-16.1) achieved a partial response.

14 econd course 1 month later for patients with partial response.

15 7_G778insGSP mutation and achieved a durable partial response.

16 gically, and only 2-3% of patients achieve a partial response.

17 l response rate (ORR) defined as complete or partial response.

18 aematological recovery, and two (10%) showed partial response.

19 achieving a complete response and 21 (58%) a partial response.

20 achieved a complete response and 21 (17%) a partial response.

21 CR and 6 months in those who had obtained a partial response.

22 ad a complete response and seven (27%) had a partial response.

23 the objective response rate was 2.9%, with 1 partial response.

24 ) had a complete response, and 4 (18%) had a partial response.

25 nts with a complete response and five with a partial response.

26 h stable disease and one patient (3.4%) with partial response.

27 at trial entry, 348 (62%) had a complete or partial response.

28 with a complete response and 24 (31%) with a partial response.

29 Four (5%; 95% CI 1.5-13.4) patients had a partial response.

30 18-57]) of 25 patients achieved a sustained partial response.

31 patients had complete responses, and 12% had partial responses.

32 as 38% with two complete responses and seven partial responses.

33 , including two complete responses and eight partial responses.

34 onse, including one complete response and 21 partial responses.

35 There were two complete responses and seven partial responses.

36 ng nine (6%) complete responses and 18 (11%) partial responses.

37 nfirmed complete response and five confirmed partial responses.

38 (11% [2-29]) complete and four (15% [4-34]) partial responses.

39 s, including eight complete responses and 20 partial responses.

40 th five (9%) complete responses and 44 (79%) partial responses.

41 11 (61%) achieved an objective (complete or partial) response.

42 s were observed, with confirmed complete and partial responses 12 mo after treatment in 19 of 28 pati

43 Of the 25 patients, 10 (40%) had a partial response, 13 (52%) had stable disease, and two (

44 ), very good partial response (9 [19%]), and partial response (16 [33%]); median duration of response

45 By day 42, four patients (11%) had a partial response, 16 (43%) had stable invasive fungal di

46 response categories: 10 cases as complete or partial response, 17 cases as stable disease, 5 cases as

47 e response (CR), 2 CRs in target lesions, 25 partial responses, 18 responses of stable disease, 2 une

48 Results: Of 7 patients, 4 had partial response, 2 had disease stabilization, and one h

49 was found between patients with complete or partial response (210 Gy; 95% CI, 161-274 Gy; n = 13) an

50 plete responses (CRs; 14.7%) and 8 very-good-partial responses (23.5%).

51 Five patients (15.6%) had a confirmed partial response, 24 patients (75%) had stable disease,

52 onse, 12%; complete response, 10%; very good partial response, 28%; and partial response, 36%) and 10

53 izumab was 56% (complete response [24%] plus partial response [32%]; 95% CI, 41.3% to 70.0%), with OR

54 umors (grade 3 or 4) (complete response, 0%; partial response, 33%; SD or DP, 67%) (P < .001).

55 e, 10%; very good partial response, 28%; and partial response, 36%) and 100% among high-risk patients

56 in 87% of patients (complete response, 49%; partial response, 38%; stable disease [SD] or local dise

57 (32.0% vs 24.6%) and achieved a complete or partial response (45.3% vs 41.0%) but this did not achie

58 rozole groups ( P = .20; complete response + partial response, 54.3% v 49.5%), and progressive diseas

59 esponded (3% complete response, 7% very good partial response, 58% partial response).

60 se rate was 21% (complete response = 4 [8%]; partial response = 7 [13%]) and 10 (19%) patients had st

61 A patient with metastatic RCC experienced a partial response (78% shrinkage, progression-free surviv

62 n (n = 12) was 100% (complete response, 92%; partial response, 8%).

63 red eleven of 126 patients had a complete or partial response (88%; 95% CI, 81% to 93%), of whom 88 h

64 sponse/complete response (4 [8%]), very good partial response (9 [19%]), and partial response (16 [33

65 ents with an objective response (complete or partial response according to Response Evaluation Criter

66 entrally assessed), defined as a complete or partial response according to the 2007 International Wor

67 t cancer achieved an objective response (all partial responses) according to RECIST.

68 the proportion of patients with complete or partial response, according to independent central revie

69 Patients with less than partial response after 3 cycles received oral dexamethas

70 SCLC patients that had clinically achieved a partial response after dacomitinib treatment.

71 isk for an early progression with at least a partial response after four or more cycles of first-line

72 d with two lines of therapy (with at least a partial response after second-line therapy); had receive

73 g Group criteria who had achieved at least a partial response after undergoing standard-of-care induc

74 ad a partial response, and 1 had a very good partial response; all 7 patients responded during the fi

75 roup analyses, participants who demonstrated partial response also experienced clinically meaningful

76 One vs 5 patients had a partial response and 12 vs 14 patients had stable diseas

77 ents) for patients with a RECIST complete or partial response and 13.3 months (8.1-20.1; 171 events)

78 thelial ovarian cancer, ten (36%) achieved a partial response and 14 (50%) had stable disease accordi

79 omplete response (non-CMR): 15 patients with partial response and 17 with disease progression.

80 (56%) of 335 women with a RECIST complete or partial response and 73 (42%) of 172 women with RECIST s

81 One patient achieved a partial response and experienced significant improvement

82 ine BRCA1 ovarian cancer achieved RECISTv1.1 partial response and Gynecologic Cancer Intergroup CA125

83 response; five (29%) experienced a confirmed partial response and have been on study for more than 2

84 We conclude that survival with a complete or partial response and no previous secondary systemic trea

85 The observed clinical activity (partial response and prolonged progression-free survival

86 6.7) had objective responses, including four partial responses and five complete responses.

87 l responses in three patients, including two partial responses and one complete response.

88 ere categorized into responders (complete or partial response) and nonresponders (stable or progressi

89 f 42 patients had an objective response (all partial responses) and 14 (33%; 20-50) had 6-month non-p

90 CI, 25.3% to 44.2%; 4 complete responses, 32 partial responses), and disease control rate was 52.4% (

91 MRD-negative complete responses, and 1 had a partial response, and 1 had a very good partial response

92 (23%) had a complete response, 2 (9%) had a partial response, and 6 (27%) had decreased tumor burden

93 ion, low posttreatment CA 19-9 level, RECIST partial response, and reduction in tumor volume were con

94 Complete response, partial response, and stable disease as best response we

95 ad a complete response, five of 20 who had a partial response, and three of five who had a minor resp

96 %); four patients (17%) achieved a confirmed partial response, and three patients (13%) had stable di

97 t cancers, 1 had a complete response, 11 had partial responses, and 66 had stable disease.

98 rate was 26%, including one complete and 11 partial responses, and the median PFS was 4.8 months.

99 disease at baseline achieved a radiographic partial response; and of 27 patients with informative un

100 A total of 35 patients (70%) had a confirmed partial response as of March 29, 2019, and 28 of these p

101 ents with an objective response (complete or partial response) as assessed by an independent radiolog

102 tients with an overall response (complete or partial response) as assessed by the investigators accor

103 ents with an objective response (complete or partial response) as per Response Evaluation Criteria in

104 an objective response (complete response or partial response), as assessed by the investigator using

105 int was an objective response (a complete or partial response), as determined by an independent revie

106 percentage of patients who had a complete or partial response), as judged by an independent review co

107 lete responses at 120 mg once a day, and one partial response at 80 mg once a day), and six additiona

108 n, absence of complete response or very good partial response at day 28 after ruxolitinib could be co

109 , three patients with liposarcoma achieved a partial response (at 250, 400, and 500 mg), 31 showed st

110 t was tumor response (complete response plus partial response) at 3 mo.

111 t was overall response (complete response or partial response) at day 28.

112 response, unconfirmed complete response, and partial response) at the end of induction.

113 e of autopleurodesis, defined as complete or partial response based on symptomatic and radiographic c

114 om baseline to a final value </=133 mumol/L, partial response by a decrease >/=50% of sCr from baseli

115 Patients not attaining at least a partial response by European LeukemiaNet criteria after

116 l benefit rate (stable > 6 months [n = 7] or partial response by RECIST criteria [n = 3]) was 26.3% (

117 patients achieving an objective (complete or partial) response by central review after six cycles of

118 f 39 patients had an objective response (all partial responses) by 6 months; in patients with osteosa

119 Three women achieved a partial response (CNS objective response rate, 8%; 95% C

120 Complete and partial responses combined were between 26.7% and 65%.

121 93% MMRD lesions responded in patients with partial response/complete response).

122 Forty patients with complete or partial response completed 2 years of study treatment, a

123 ng response categories: 10 cases as complete/partial response (CR/PR), 17 cases with stable disease (

124 aracteristics analysis identified a low-dFLC partial response (dFLC <10 mg/L for patients with a dFLC

125 , and 19 patients (47.5%) achieved very good partial response (dFLC <40 mg/L) or better.

126 e (final cutaneous ePOST score of 0 or 1) or partial response (ePOST drop >/=2 points from baseline b

127 o relapsed was retreated and has remained in partial response for more than 23 months.

128 patients (9 adults and 7 children), 1 had a partial response for more than 9 months, 7 had stable di

129 Five (20%) patients had a partial response, for an objective response of 20% (95%

130 Very good partial response (free light chain reduction >= 90%) or

131 Two partial responses (>/= 18 months, >/= 7 months) and seve

132 Six partial responses (>/= 5 to >/= 8 months) and three stab

133 Two partial responses (>/=15 months and >/= 11 months) and e

134 At 8 weeks, 38 complete responses and 16 partial responses had been achieved, with the median Dis

135 where the majority of dogs achieve complete/partial response; however, it is very important to predi

136 lete response unconfirmed in three (8%), and partial response in 12 (32.4%) for an overall response r

137 b was 76%, including CR in 36% and very good partial response in 24%.

138 Treatment with 74 kBq induced a partial response in 7 of 7 tumors, but from 42 d, 6 of 7

139 mission was observed in one patient with TC, partial response in five patients (T, n = 3; TC, n = 2),

140 .5%), major response in three (23.1%), and a partial response in three (23.1%) patients, whereas two

141 after RLT), CXCR4-directed RLT resulted in a partial response in two (both treated with additional ra

142 phase-I clinical trials and early data show partial responses in nearly half of patients with lung c

143 (95% CI, 29.6% to 56.7%), respectively, with partial responses in seven (13.0%) and eight (14.5%) pat

144 portion of patients who achieved complete or partial response) in all patients and by PD-L1 expressio

145 est overall response of complete response or partial response) in patients with measurable disease at

146 se rate was 77% (15 complete responses and 8 partial responses) in 30 evaluable patients.

147 %) demonstrated at least stable disease or a partial response, indicating that some G3 NENs can be re

148 ble disease (k=0.90, percent agreement=95%), partial response (k=0.96, percent agreement=98.1%) and c

149 sis, 2 (12.5%) patients achieved a confirmed partial response (lasting for 8.0 and 18.1 months, respe

150 %, with 49% complete response (CR)/very good partial response/low dFLC response and with a stringent

151 response (a composite of complete response, partial response, marrow complete response, and haematol

152 erall survival (OS) compared with near-CR or partial response (median PFS, 27, 27, and 29 months, res

153 [21-61]) of 25 patients achieved a sustained partial response; median follow-up was 48.60 months (IQR

154 sponse will be defined as complete response, partial response, minor response, stable disease, or pro

155 Complete response (n = 0), partial response (n = 8), or stable disease (n = 6) was

156 Complete response (n = 0), partial response (n = 9), or stable disease (n = 11) was

157 se was as follows: complete response, n = 1; partial response, n = 11; stable disease, n = 17; and pr

158 e confirmed objective response rate was 30% (partial response, n = 19; complete response, n = 2), the

159 responses to TAE (complete response, n = 6; partial response, n = 5) and 11 patients were nonrespond

160 e, there was one complete response and seven partial responses (objective response rate 19%, 95% CI 9

161 ogic response in 15 (54%) patients; at least partial response occurred in 20, 22, and 17 patients at

162 Hematologic complete and very-good-partial response occurred in 86% of patients.

163 e increased the ORR with all responses of >/=partial response occurring in the 45 mg/m(2) selinexor p

164 A radiologically complete or partial response occurs more often in patients using the

165 Computed tomography revealed partial response of hepatic metastases in 7 patients (25

166 Two patients (4.4%) had a partial response; one had squamous cell carcinoma (SCC)

167 was 21% (14/66), and 15% achieved very good partial response or better (>/=VGPR).

168 ORR) was 67% (44/66); 42% achieved very good partial response or better (>/=VGPR).

169 ding 20 (14%) of 148 patients with very good partial response or better (8.5-20.1) and seven (5%) pat

170 dies are generally well tolerated and induce partial response or better in approximately 30% of heavi

171 nd yielded an overall response rate (ORR) of partial response or better of 95.8% (95% confidence inte

172 A partial response or better was observed in 26% of patien

173 nduction (n = 426), the rates of a very good partial response or better were 55.6% by cycle 3, 63.8%

174 All 16 patients who had a response (partial response or better) and who could be evaluated f

175 primary end point was overall response rate (partial response or better) assessed by the investigator

176 nvolvement; (2) lack of improvement in GVHD (partial response or better) compared with baseline after

177 The rates of overall response (partial response or better) were 82% (176/216) in the VR

178 ysis among patients who attained a very good partial response or better, the monotypic PCs at the 0.1

179 end point was overall response, defined as a partial response or better, with response assessed by an

180 f 98 patients given melphalan alone achieved partial response or better.

181 e was observed in 68% of patients (very good partial response or complete response in 29%), as well a

182 No partial response or complete response was observed.

183 with a stratum-specific objective response (partial response or complete response), as assessed by t

184 ients achieving a brain metastasis response (partial response or complete response, according to mREC

185 ressing memory signatures than patients with partial response or progressive disease.

186 whom had platinum-refractory disease, had a partial response or prolonged stable disease (10, >/= 6,

187 ients with evaluable disease, 59 (92%) had a partial response or stable disease as the best objective

188 olizumab, 13/16 (81.3%) patients who achieve partial response or stable disease express high levels o

189 nical benefit rate (defined as a complete or partial response or stable disease for at least 6 months

190 days apart; repeated at 6 months in case of partial response) or oral cyclosporine (starting at a do

191 e of clinical benefit-defined as complete or partial response, or as stable disease beyond 16 weeks-o

192 e (fraction of patients with stable disease, partial response, or complete response) to therapy.

193 mplete response, very good partial response, partial response, or minor response) compared with only

194 the target lesions showed complete response, partial response, or stable disease (disease control) at

195 ment at month 9 showing a complete response, partial response, or stable disease according to local R

196 rall lesion assessment of complete response, partial response, or stable disease was 16 of 41 patient

197 r exhibited OR (one complete response, three partial responses; OR rate, 26.7%; 95% CI, 7.8% to 55.1%

198 ion of patients with a confirmed complete or partial response over placebo plus pemetrexed-platinum i

199 n of proven or suspected lesion due to ECD), partial response (partial resolution of proven or suspec

200 e resolution of symptoms attributed to ECD), partial response (partial resolution of symptoms attribu

201 therapy (either complete response, very good partial response, partial response, or minor response) c

202 ho achieved a confirmed complete response or partial response per Response Evaluation Criteria In Sol

203 s objective response (complete responses and partial responses per RECIST 1.1).

204 The spectral data were analyzed using partial response plots, and identified non-linearity mod

205 an overall response (complete responses plus partial responses plus minor responses) after each treat

206 Response rates by RECIST: partial response (PR) 21% (17/82), stable disease (SD) 4

207 ient-reported outcomes in patients who had a partial response (PR) and complete response (CR) to thei

208 failure was defined as failure to achieve a partial response (PR) by the end of the 4-week induction

209 tly higher in patients who achieved at least partial response (PR) compared with patients who achieve

210 upfront window; those with complete (CR) or partial response (PR) had VI incorporated into regimen U

211 Best response was partial response (PR) in four patients [(overall respons

212 Patients with a confirmed partial response (PR) or complete response (CR) within 6

213 difference in day 28 complete response (CR)/partial response (PR) rates for sirolimus vs prednisone

214 BCL who achieved a complete response (CR) or partial response (PR) to R-CHOP induction.

215 lded two continuous complete remissions, one partial response (PR) using RECIST criteria (two PRs usi

216 A partial response (PR) was a secondary end point, defined

217 tic value of different parameters defining a partial response (PR) was further investigated.

218 nts who achieved a complete response (CR) or partial response (PR) with or without second-look surger

219 s at our institution who achieved at least a partial response (PR) with various therapies between 199

220 achieved complete response (CR) and 14 (31%) partial response (PR).

221 patients achieved complete response (CR) or partial response (PR).

222 response rate (complete response [CR] and/or partial response [PR]) by International Workshop on Chro

223 in the VTD arm achieved at least a very good partial response (primary end point) vs 56.2% in the VCD

224 nt scales (complete response, indeterminate, partial response, progressive disease).

225 ividual response classes (complete response, partial response, progressive disease, or stable disease

226 two groups: ORR 16% (complete response [CR]/partial responses[PRs], 32) versus 13% (CR/PRs, 13); med

227 Similar to imatinib, the partial response rate for regorafenib by Choi (29%) was

228 e infusion produced a cumulative complete or partial response rate of 92% (95% CI, 78.1% to 98.3%) ov

229 (objective response rate, 85%; CR rate, 37%; partial response rate, 48%) and eligibility for surgery

230 Partial response rates were 0% (none of six), 10% (two o

231 54 Gy radiation, and 20 (45%) with less than partial responses received 60 Gy.

232 nd 73 patients (19.7%) achieved complete and partial response, respectively.

233 onse after the redosing cycle; 15 (41%) with partial responses, seven (19%) with minor responses.

234 Antitumor activity (seven partial responses [six confirmed]) was demonstrated with

235 d clinical benefit rate (complete response + partial response + stable disease >/= 4 months), 43%.

236 e clinical benefit rate (complete response + partial response + stable disease >/= 6 months) was 46%.

237 Complete and partial response, stable disease, and progressive diseas

238 red all the response categories: complete or partial response, stable disease, progressive disease, a

239 ty was lower among patients with complete or partial response than among those with stable or progres

240 was 84% higher in patients with complete or partial response than in patients with progressive disea

241 l, five of 23 patients (21.7%) met PFS3 (two partial response, three stable disease).

242 cal efficacy was noted in five patients (two partial response, three stable disease).

243 asurable disease at baseline had a confirmed partial response; thus, the proportion of patients achie

244 ent had a complete response and 17 (30%) had partial responses; thus overall 18 of 57 patients achiev

245 kin lymphoma, two had complete and seven had partial responses; thus, nine patients achieved an objec

246 tem with autoimmune pathogenesis, have shown partial response to a number of immunomodulating treatme

247 lity criteria and showed at least an initial partial response to a single intravenous infusion of ket

248 n index patient with NOTCH1-mutant ACC had a partial response to brontictuzumab.

249 e III-IV EOC whose disease is in complete or partial response to first-line, platinum-based chemother

250 Patients with complete or partial response to IC received 61.2 Gy to the nasophary

251 n patients who did not experience at least a partial response to IC, the 5-year DSS probabilities wer

252 of identified CAPS patients who show only a partial response to IL-1 blockade.

253 ensified the Ala92-Dio2 phenotype, with only partial response to LT4 therapy.

254 Interestingly, complete response but not partial response to MSCs was associated with overall sur

255 itive ovarian cancer following a complete or partial response to second-line or later platinum-based

256 motherapy regimens, had achieved complete or partial response to their last platinum-based regimen, h

257 However, most patients did show a partial response to vaccination.

258 There were 7 complete responses and 8 partial responses to combination carmustine and O6-benzy

259 rapeutic implications for CAPS patients with partial responses to IL-1-targeted therapies.

260 24 (55%) patients with complete or partial responses to induction chemotherapy received 54

261 -determined overall response-ie, complete or partial response (treatment success) or stable or progre

262 solid tumours and other lymphomas, eight had partial responses (two patients each with adrenocortical

263 mong the responders, six patients achieved a partial response, two of which are ongoing and have not

264 ssociated with inferior PFS, whereas DHL and partial response ( v complete response) at transplant we

265 ving a complete response (CR) or a very good partial response (VGPR) by independent review.

266 ht chain (FLC) response, including very good partial response (VGPR) or above in 52%.

267 with 89.9% of patients achieving a very good partial response (VGPR) or better and 33.3% achieving st

268 with risk, patients relapsing from very good partial response (VGPR) or better had a longer time to d

269 The rate of better than very good partial response (VGPR) was higher in more recent period

270 available (uncertain CR; uCR), or very good partial response (VGPR).

271 esponse for the four patients who achieved a partial response was 5.4 months (4.1 to 7.5 months).

272 ation of response for patients with at least partial response was 64.5 months.

273 A partial response was achieved and remained for more than

274 te response was defined as zero lesions, and partial response was defined as a 50% or greater reducti

275 defined by a >=35% decrease in Y-BOCS score, partial response was defined by a 25%-34% decrease, and

276 ormalisation of all affected lineages, and a partial response was defined in neutropenic patients as

277 Immune-related partial response was observed in another patient with me

278 w-up, a best overall response of complete or partial response was recorded in 27 patients (17%; 95% C

279 The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [C

280 ng rates of complete response plus very good partial response were 48% and 39%.

281 Patients achieving at least a partial response were randomly assigned to receive maint

282 survival (PFS) of patients with complete and partial response were statistically comparable.

283 onses were achieved in six (3%) patients and partial responses were achieved in 134 (67%) patients.

284 Partial responses were also observed in one (6%, 95% CI

285 Objective partial responses were observed in 66 (48%; 95% CI 39-56

286 treated at the highest dose level, objective partial responses were observed in a patient with esopha

287 Partial responses were observed in one patient with uvea

288 Partial responses were observed in seven of nine patient

289 Partial responses were recorded in ten of 26 patients in

290 Confirmed partial responses were seen in 8% (90% CI, 3% to 18%) an

291 Objective (complete or partial) responses were observed in nine (52.9%) of 17 r

292 onses, including 4 complete responses and 18 partial responses, which were observed across a spectrum

293 govitecan treatment; one patient achieved a partial response with a sustained response spanning > 2

294 itumor activity were observed: 1 unconfirmed partial response with a time to progression of 23 weeks

295 The overall response rate, including partial response with lymphocytosis, with acalabrutinib

296 Success was defined as complete or partial response with no secondary systemic treatment or

297 ients achieved a CR and seven (13%) achieved partial responses with negative markers (PR-negative) fo

298 1 of 17] complete response and 46% [8 of 17] partial response), with 18% (3 of 17) stable disease and

299 logical response rate was 54% (8 of 15) (all partial response), with 26% (4 of 15) stable disease and

300 hirteen (33%) additional patients achieved a partial response, with a reduction in the PSA level to l